Search tips
Search criteria 


Logo of thoraxThoraxVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Thorax. 2005 October; 60(10): 848–850.
Published online 2005 July 29. doi:  10.1136/thx.2005.041798
PMCID: PMC1747199

Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health Improvement Network


Background: Bupropion is an effective smoking cessation therapy but its use in the UK has been limited by concerns that it may increase the risk of sudden death.

Methods: Data for all patients prescribed bupropion within The Health Improvement Network (a computerised general practice database) were extracted and the self-controlled case-series method was used to estimate the relative incidence of death during the first 28 days of treatment. The incidence of seizures, a recognised adverse effect of bupropion, was also investigated during this period.

Results: A total of 9329 individuals had been prescribed bupropion (mean age 44 years, 48% male). The total person-time after the first prescription for bupropion was 17 586 years, and during this time 121 people died. Two people died within the first 28 days of treatment, which was less than expected in comparison with the remaining observation period by an incidence ratio of 0.50 (95% confidence interval (CI) 0.12 to 2.05). Twenty eight people were recorded as having a total of 45 seizures (23 before starting bupropion, two in the first 28 days of treatment, and 20 at a later point). The relative incidence of seizures during the first 28 days of treatment was 3.62 (95% CI 0.87 to 15.09), equivalent to one additional seizure per 6219 first time bupropion users.

Conclusions: Bupropion use is probably associated with an increased risk of seizures, but no evidence was found to suggest that the drug is associated with an increased risk of sudden death.

Full Text

The Full Text of this article is available as a PDF (59K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax. 2000 Dec;55(12):987–999. [PMC free article] [PubMed]
  • Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Jr, Enright PL, Kanner RE, O'Hara P, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994 Nov 16;272(19):1497–1505. [PubMed]
  • Bourke Alison, Dattani Hassy, Robinson Michael. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care. 2004;12(3):171–177. [PubMed]
  • Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol. 1996 Jun 1;143(11):1165–1173. [PubMed]
  • Farrington P, Pugh S, Colville A, Flower A, Nash J, Morgan-Capner P, Rush M, Miller E. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet. 1995 Mar 4;345(8949):567–569. [PubMed]
  • Hubbard Richard, Farrington Paddy, Smith Chris, Smeeth Liam, Tattersfield Anne. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol. 2003 Jul 1;158(1):77–84. [PubMed]
  • Dunner DL, Zisook S, Billow AA, Batey SR, Johnston JA, Ascher JA. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry. 1998 Jul;59(7):366–373. [PubMed]
  • Walley T, Mantgani A. The UK General Practice Research Database. Lancet. 1997 Oct 11;350(9084):1097–1099. [PubMed]
  • Settle EC., Jr Bupropion sustained release: side effect profile. J Clin Psychiatry. 1998;59 (Suppl 4):32–36. [PubMed]
  • Johnston JA, Lineberry CG, Ascher JA, Davidson J, Khayrallah MA, Feighner JP, Stark P. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry. 1991 Nov;52(11):450–456. [PubMed]
  • Pisani Francesco, Oteri Giancarla, Costa Cinzia, Di Raimondo Giorgio, Di Perri Raoul. Effects of psychotropic drugs on seizure threshold. Drug Saf. 2002;25(2):91–110. [PubMed]
  • Boshier Andrew, Wilton Lynda V, Shakir Saad A W. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol. 2003 Dec;59(10):767–773. [PubMed]

Articles from Thorax are provided here courtesy of BMJ Group